COMMUNIQUÉS West-GlobeNewswire

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
18/11/2024
- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Mortality (ACM) alone at [...]
Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA
18/11/2024
SAN FRANCISCO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneer of AAV immuno-gene therapy for cancer, today revealed its lead asset, SRN-101, for the treatment of high-grade gliomas. The FDA granted both [...]
Novo Nordisk A/S - share repurchase programme
18/11/2024
Bagsværd, Denmark, 18 November 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April [...]
Alkeus Pharmaceuticals Receives FDA Rare Pediatric Disease and Fast Track Designations for Gildeuretinol as a Treatment for Stargardt Disease
18/11/2024
Designations underscore significant unmet need in Stargardt disease, a rare and serious pediatric disease for which no treatment exists. Data from Alkeus’ TEASE program were presented at the American Academy of [...]
SoldierStrong Announces Annual SoldierScholar Recipients for 2024
18/11/2024
STAMFORD, Conn., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Delivering on its commitment to assist military veterans in taking a significant academic step forward in life after service, the national nonprofit SoldierStrong today [...]
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
18/11/2024
- IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to placebo – - Top-line [...]
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
18/11/2024
Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical study for managing severe conditions The Company is currently developing SPC-15 as an intranasal [...]
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
18/11/2024
ALLO-329 Induces Deep, Transient Depletion of CD19+ B Cells and CD70+ T Cells, and Reduction in IgG and IgM without Lymphodepletion in Humanized Murine Models Proprietary Dagger ® Technology Enables ALLO-329 to Overcome [...]
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
18/11/2024
Actively Exploring Partnership for Alzheimer’s Development Supplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company [...]
Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
18/11/2024
Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugs Appointment initiates Cassava’s commercial readiness strategy as the Company prepares for [...]
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
18/11/2024
FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that the Nasdaq Listing Qualifications Hearings Panel ( [...]
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
18/11/2024
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted [...]
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit
18/11/2024
SOLANA BEACH, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people [...]
FOXO TECHNOLOGIES INC.’S BOARD OF DIRECTORS ANNOUNCES SPECIAL MEETING OF SHAREHOLDERS
18/11/2024
MINNEAPOLIS, MN, Nov. 18, 2024 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (the “Company” or “FOXO”), will hold a Special Meeting of its Shareholders at 10.30am EST on Friday, November 29, 2024. The [...]
Cerevance Doses First Patient in Pivotal Phase 3 ARISE Trial of Solengepras for Treatment of Parkinson’s Disease
18/11/2024
Solengepras is a potentially first-in-class, oral, non-dopaminergic investigational therapy in development for Parkinson’s disease ARISE will evaluate the efficacy of solengepras as an adjunctive therapy to levodopa and [...]
Aclaris Therapeutics Announces $80 Million Private Placement
18/11/2024
WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno- [...]
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
18/11/2024
- Enhances Aclaris’ pipeline with complementary biologics portfolio - - Expands leadership team with addition of seasoned biotech executives - - Management to host conference call today at 8:30 AM ET - WAYNE, Pa., Nov. [...]
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
18/11/2024
27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies Patient Treated with [...]
Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device
18/11/2024
Management to host business update call today at 9:00am ET NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on [...]

Pages